Article
The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population.
Thrombosis research - 1 Sept 2012
Isordia-Salas Irma, Olalde-Román Marcos Jaciel, Santiago-Germán David, de la Peña Norma Corona, Valencia-Sánchez Jesús Salvador
Abstract excerpt
INTRODUCTION: Clopidogrel is recommended in addition to aspirin to prevent atherothrombotic events in patients with acute coronary syndromes (ACS) and in those undergoing percutaneous coronary intervention (PCI). However, an interindividual variability in platelet inhibition response to clopidogrel has been demonstrated, and is associated with recurrent cardiovascular events. Multiple mechanisms have been...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
